Literature DB >> 22037780

A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance.

Catherine Meads1, Ikhlaaq Ahmed, Richard D Riley.   

Abstract

A risk prediction model is a statistical tool for estimating the probability that a currently healthy individual with specific risk factors will develop a condition in the future such as breast cancer. Reliably accurate prediction models can inform future disease burdens, health policies and individual decisions. Breast cancer prediction models containing modifiable risk factors, such as alcohol consumption, BMI or weight, condom use, exogenous hormone use and physical activity, are of particular interest to women who might be considering how to reduce their risk of breast cancer and clinicians developing health policies to reduce population incidence rates. We performed a systematic review to identify and evaluate the performance of prediction models for breast cancer that contain modifiable factors. A protocol was developed and a sensitive search in databases including MEDLINE and EMBASE was conducted in June 2010. Extensive use was made of reference lists. Included were any articles proposing or validating a breast cancer prediction model in a general female population, with no language restrictions. Duplicate data extraction and quality assessment were conducted. Results were summarised qualitatively, and where possible meta-analysis of model performance statistics was undertaken. The systematic review found 17 breast cancer models, each containing a different but often overlapping set of modifiable and other risk factors, combined with an estimated baseline risk that was also often different. Quality of reporting was generally poor, with characteristics of included participants and fitted model results often missing. Only four models received independent validation in external data, most notably the 'Gail 2' model with 12 validations. None of the models demonstrated consistently outstanding ability to accurately discriminate between those who did and those who did not develop breast cancer. For example, random-effects meta-analyses of the performance of the 'Gail 2' model showed the average C statistic was 0.63 (95% CI 0.59-0.67), and the expected/observed ratio of events varied considerably across studies (95% prediction interval for E/O ratio when the model was applied in practice was 0.75-1.19). There is a need for models with better predictive performance but, given the large amount of work already conducted, further improvement of existing models based on conventional risk factors is perhaps unlikely. Research to identify new risk factors with large additionally predictive ability is therefore needed, alongside clearer reporting and continual validation of new models as they develop.

Entities:  

Mesh:

Year:  2011        PMID: 22037780     DOI: 10.1007/s10549-011-1818-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  67 in total

1.  Developing a utility decision framework to evaluate predictive models in breast cancer risk estimation.

Authors:  Yirong Wu; Craig K Abbey; Xianqiao Chen; Jie Liu; David C Page; Oguzhan Alagoz; Peggy Peissig; Adedayo A Onitilo; Elizabeth S Burnside
Journal:  J Med Imaging (Bellingham)       Date:  2015-08-17

2.  Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.

Authors:  Wenzhen Ge; Tess V Clendenen; Yelena Afanasyeva; Karen L Koenig; Claudia Agnoli; Louise A Brinton; Joanne F Dorgan; A Heather Eliassen; Roni T Falk; Göran Hallmans; Susan E Hankinson; Judith Hoffman-Bolton; Timothy J Key; Vittorio Krogh; Hazel B Nichols; Dale P Sandler; Minouk J Schoemaker; Patrick M Sluss; Malin Sund; Anthony J Swerdlow; Kala Visvanathan; Mengling Liu; Anne Zeleniuch-Jacquotte
Journal:  Int J Cancer       Date:  2018-02-08       Impact factor: 7.396

3.  Improving breast cancer risk prediction by using demographic risk factors, abnormality features on mammograms and genetic variants.

Authors:  Shara I Feld; Kaitlin M Woo; Roxana Alexandridis; Yirong Wu; Jie Liu; Peggy Peissig; Adedayo A Onitilo; Jennifer Cox; C David Page; Elizabeth S Burnside
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

4.  Development of a risk assessment tool for projecting individualized probabilities of developing breast cancer for Chinese women.

Authors:  Yuan Wang; Ying Gao; Munkhzul Battsend; Kexin Chen; Wenli Lu; Yaogang Wang
Journal:  Tumour Biol       Date:  2014-08-02

5.  How Do Women View Risk-Based Mammography Screening? A Qualitative Study.

Authors:  Xiaofei He; Karen E Schifferdecker; Elissa M Ozanne; Anna N A Tosteson; Steven Woloshin; Lisa M Schwartz
Journal:  J Gen Intern Med       Date:  2018-07-31       Impact factor: 5.128

6.  A focus group study on breast cancer risk presentation: one format does not fit all.

Authors:  Michel Dorval; Karine Bouchard; Jocelyne Chiquette; Gord Glendon; Christine M Maugard; Wilhelm Dubuisson; Seema Panchal; Jacques Simard
Journal:  Eur J Hum Genet       Date:  2012-11-21       Impact factor: 4.246

7.  Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools.

Authors:  Sarina Schrager; Elizabeth Burnside
Journal:  J Womens Health (Larchmt)       Date:  2018-05-14       Impact factor: 2.681

8.  Assessing breast cancer risk models in Marin County, a population with high rates of delayed childbirth.

Authors:  Mark Powell; Farid Jamshidian; Kate Cheyne; Joanne Nititham; Lee Ann Prebil; Rochelle Ereman
Journal:  Clin Breast Cancer       Date:  2013-11-22       Impact factor: 3.225

9.  Quantifying the Polygenic Contribution to Cutaneous Squamous Cell Carcinoma Risk.

Authors:  Joanne E Sordillo; Peter Kraft; Ann Chen Wu; Maryam M Asgari
Journal:  J Invest Dermatol       Date:  2018-02-13       Impact factor: 8.551

10.  Developing a clinical utility framework to evaluate prediction models in radiogenomics.

Authors:  Yirong Wu; Jie Liu; Alejandro Munoz Del Rio; David C Page; Oguzhan Alagoz; Peggy Peissig; Adedayo A Onitilo; Elizabeth S Burnside
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2015-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.